<VariationArchive VariationID="548594" VariationName="NM_002693.3(POLG):c.1615_1623del (p.Phe539_Gln541del)" VariationType="Deletion" Accession="VCV000548594" Version="11" RecordType="classified" NumberOfSubmissions="5" NumberOfSubmitters="3" DateLastUpdated="2024-02-20" DateCreated="2018-07-13" MostRecentSubmission="2024-02-14">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="539063" VariationID="548594">
      <GeneList>
        <Gene Symbol="POLG" FullName="DNA polymerase gamma, catalytic subunit" GeneID="5428" HGNC_ID="HGNC:9179" Source="submitted" RelationshipType="within multiple genes by overlap">
          <Location>
            <CytogeneticLocation>15q26.1</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="15" Accession="NC_000015.10" start="89316320" stop="89334824" display_start="89316320" display_stop="89334824" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="15" Accession="NC_000015.9" start="89859535" stop="89878025" display_start="89859535" display_stop="89878025" Strand="-" />
          </Location>
          <OMIM>174763</OMIM>
        </Gene>
        <Gene Symbol="POLGARF" FullName="POLG alternative reading frame" GeneID="125316803" HGNC_ID="HGNC:56246" Source="calculated" RelationshipType="within multiple genes by overlap">
          <Location>
            <CytogeneticLocation>15q26.1</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="15" Accession="NC_000015.10" start="89316320" stop="89334824" display_start="89316320" display_stop="89334824" Strand="-" />
          </Location>
        </Gene>
      </GeneList>
      <Name>NM_002693.3(POLG):c.1615_1623del (p.Phe539_Gln541del)</Name>
      <CanonicalSPDI>NC_000015.10:89326700:TTGTTGAAA:</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>15q26.1</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="15" Accession="NC_000015.10" start="89326701" stop="89326709" display_start="89326701" display_stop="89326709" variantLength="9" positionVCF="89326700" referenceAlleleVCF="CTTGTTGAAA" alternateAlleleVCF="C" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="15" Accession="NC_000015.9" start="89869932" stop="89869940" display_start="89869932" display_stop="89869940" variantLength="9" positionVCF="89869931" referenceAlleleVCF="CTTGTTGAAA" alternateAlleleVCF="C" />
      </Location>
      <HGVSlist>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_002693.2" sequenceAccession="NM_002693" sequenceVersion="2" change="c.1615_1623delTTTCAACAA">
            <Expression>NM_002693.2:c.1615_1623delTTTCAACAA</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_765" sequenceAccession="LRG_765">
            <Expression>LRG_765:g.13087_13095del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="LRG_765t1" sequenceAccession="LRG_765t1">
            <Expression>LRG_765t1:c.1615_1623del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000015.10" sequenceAccession="NC_000015" sequenceVersion="10" change="g.89326701_89326709del" Assembly="GRCh38">
            <Expression>NC_000015.10:g.89326701_89326709del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000015.9" sequenceAccession="NC_000015" sequenceVersion="9" change="g.89869932_89869940del" Assembly="GRCh37">
            <Expression>NC_000015.9:g.89869932_89869940del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_008218.2" sequenceAccession="NG_008218" sequenceVersion="2" change="g.13087_13095del">
            <Expression>NG_008218.2:g.13087_13095del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001126131.2" sequenceAccession="NM_001126131" sequenceVersion="2" change="c.1615_1623del">
            <Expression>NM_001126131.2:c.1615_1623del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001119603.1" sequenceAccession="NP_001119603" sequenceVersion="1" change="p.Phe539_Gln541del">
            <Expression>NP_001119603.1:p.Phe539_Gln541del</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001822" Type="inframe_deletion" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_002693.3" sequenceAccession="NM_002693" sequenceVersion="3" change="c.1615_1623del" MANESelect="true">
            <Expression>NM_002693.3:c.1615_1623del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_002684.1" sequenceAccession="NP_002684" sequenceVersion="1" change="p.Phe539_Gln541del">
            <Expression>NP_002684.1:p.Phe539_Gln541del</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001822" Type="inframe_deletion" DB="SO" />
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef Type="rs" ID="754586219" DB="dbSNP" />
      </XRefList>
      <AlleleFrequencyList>
        <AlleleFrequency Value="0.00000" Source="The Genome Aggregation Database (gnomAD), exomes" />
        <AlleleFrequency Value="0.00002" Source="Exome Aggregation Consortium (ExAC)" />
        <AlleleFrequency Value="0.00002" Source="The Genome Aggregation Database (gnomAD)" />
        <AlleleFrequency Value="0.00002" Source="Trans-Omics for Precision Medicine (TOPMed)" />
      </AlleleFrequencyList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_002693.3(POLG):c.1615_1623del (p.Phe539_Gln541del) AND Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant 1" Accession="RCV000662161" Version="7">
        <ClassifiedConditionList TraitSetID="3712">
          <ClassifiedCondition DB="MedGen" ID="C1834846">Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant 1</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2018-03-05" SubmissionCount="1">Uncertain significance</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_002693.3(POLG):c.1615_1623del (p.Phe539_Gln541del) AND Mitochondrial DNA depletion syndrome 4b" Accession="RCV000662162" Version="4">
        <ClassifiedConditionList TraitSetID="6257">
          <ClassifiedCondition DB="MedGen" ID="C3150914">Mitochondrial DNA depletion syndrome 4b</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2018-03-05" SubmissionCount="1">Uncertain significance</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_002693.3(POLG):c.1615_1623del (p.Phe539_Gln541del) AND Progressive sclerosing poliodystrophy" Accession="RCV000662163" Version="6">
        <ClassifiedConditionList TraitSetID="3716">
          <ClassifiedCondition DB="MedGen" ID="C0205710">Progressive sclerosing poliodystrophy</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
            <Description DateLastEvaluated="2024-01-25" SubmissionCount="2">Uncertain significance</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_002693.3(POLG):c.1615_1623del (p.Phe539_Gln541del) AND not provided" Accession="RCV003237981" Version="2">
        <ClassifiedConditionList TraitSetID="9460">
          <ClassifiedCondition DB="MedGen" ID="C3661900">not provided</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2021-11-03" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2024-01-25" NumberOfSubmissions="5" NumberOfSubmitters="3" DateCreated="2018-07-13" MostRecentSubmission="2024-02-14">
        <ReviewStatus>criteria provided, conflicting classifications</ReviewStatus>
        <Description>Conflicting classifications of pathogenicity</Description>
        <Explanation DataSource="ClinVar" Type="public">Pathogenic(1); Uncertain significance(4)</Explanation>
        <Comment DataSource="ClinVar" Type="public">Pathogenic(1); Uncertain significance(4)</Comment>
        <DescriptionHistory Dated="2021-11-05">
          <Description>Uncertain significance</Description>
        </DescriptionHistory>
        <ConditionList>
          <TraitSet ID="9460" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="17556" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">not provided</ElementValue>
                <XRef ID="13DG0619" DB="Department Of Translational Genomics (developmental Genetics Section), King Faisal Specialist Hospital &amp; Research Centre" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">none provided</ElementValue>
              </Name>
              <AttributeSet>
                <Attribute Type="public definition">The term 'not provided' is registered in MedGen to support identification of submissions to ClinVar for which no condition was named when assessing the variant. 'not provided' differs from 'not specified', which is used when a variant is asserted to be benign, likely benign, or of uncertain significance for conditions that have not been specified.</Attribute>
              </AttributeSet>
              <XRef ID="C3661900" DB="MedGen" />
            </Trait>
          </TraitSet>
          <TraitSet ID="3712" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="3384" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 1</ElementValue>
                <XRef Type="MIM" ID="157640" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant 1</ElementValue>
                <XRef ID="MONDO:0024528" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">PEOA1</ElementValue>
                <XRef Type="MIM" ID="157640" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="13174" />
                <XRef ID="13174" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">POLG-related disorders comprise a continuum of overlapping phenotypes that were clinically defined long before their molecular basis was known. Most affected individuals have some, but not all, of the features of a given phenotype; nonetheless, the following nomenclature can assist the clinician in diagnosis and management. Onset of the POLG-related disorders ranges from infancy to late adulthood. Alpers-Huttenlocher syndrome (AHS), one of the most severe phenotypes, is characterized by childhood-onset progressive and ultimately severe encephalopathy with intractable epilepsy and hepatic failure. Childhood myocerebrohepatopathy spectrum (MCHS) presents between the first few months of life and about age three years with developmental delay or dementia, lactic acidosis, and a myopathy with failure to thrive. Other findings can include liver failure, renal tubular acidosis, pancreatitis, cyclic vomiting, and hearing loss. Myoclonic epilepsy myopathy sensory ataxia (MEMSA) now describes the spectrum of disorders with epilepsy, myopathy, and ataxia without ophthalmoplegia. MEMSA now includes the disorders previously described as spinocerebellar ataxia with epilepsy (SCAE). The ataxia neuropathy spectrum (ANS) includes the phenotypes previously referred to as mitochondrial recessive ataxia syndrome (MIRAS) and sensory ataxia neuropathy dysarthria and ophthalmoplegia (SANDO). About 90% of persons in the ANS have ataxia and neuropathy as core features. Approximately two thirds develop seizures and almost one half develop ophthalmoplegia; clinical myopathy is rare. Autosomal recessive progressive external ophthalmoplegia (arPEO) is characterized by progressive weakness of the extraocular eye muscles resulting in ptosis and ophthalmoparesis (or paresis of the extraocular muscles) without associated systemic involvement; however, caution is advised because many individuals with apparently isolated arPEO at the onset develop other manifestations of POLG-related disorders over years or decades. Of note, in the ANS spectrum the neuropathy commonly precedes the onset of PEO by years to decades. Autosomal dominant progressive external ophthalmoplegia (adPEO) typically includes a generalized myopathy and often variable degrees of sensorineural hearing loss, axonal neuropathy, ataxia, depression, parkinsonism, hypogonadism, and cataracts (in what has been called "chronic progressive external ophthalmoplegia plus," or "CPEO+").</Attribute>
                <XRef ID="NBK26471" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301382</ID>
                <ID Source="BookShelf">NBK1203</ID>
              </Citation>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301791</ID>
                <ID Source="BookShelf">NBK26471</ID>
              </Citation>
              <Citation Type="general" Abbrev="MMS, 2017">
                <ID Source="PubMed">28749475</ID>
                <ID Source="pmc">7804217</ID>
              </Citation>
              <XRef ID="C1834846" DB="MedGen" />
              <XRef ID="MONDO:0024528" DB="MONDO" />
              <XRef Type="MIM" ID="157640" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="3716" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="105" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Progressive sclerosing poliodystrophy</ElementValue>
                <XRef ID="Progressive+sclerosing+poliodystrophy/9168" DB="Genetic Alliance" />
                <XRef ID="20415001" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Alpers disease</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Alpers diffuse degeneration of cerebral gray matter with hepatic cirrhosis</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Alpers progressive infantile poliodystrophy</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Poliodystrophia cerebri progressiva</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Progressive cerebral poliodystrophy</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Diffuse cerebral degeneration in infancy</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Neuronal degeneration of childhood with liver disease, progressive</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Infantile poliodystrophy</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Alpers Syndrome</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Alpers-Huttenlocher Syndrome</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Mitochondrial DNA depletion syndrome 4A (Alpers type)</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Mitochondrial DNA Depletion Syndrome 4A</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">MTDPS4A</ElementValue>
                <XRef Type="MIM" ID="203700" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">PNDC</ElementValue>
                <XRef Type="MIM" ID="203700" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">POLG-related disorders comprise a continuum of overlapping phenotypes that were clinically defined long before their molecular basis was known. Most affected individuals have some, but not all, of the features of a given phenotype; nonetheless, the following nomenclature can assist the clinician in diagnosis and management. Onset of the POLG-related disorders ranges from infancy to late adulthood. Alpers-Huttenlocher syndrome (AHS), one of the most severe phenotypes, is characterized by childhood-onset progressive and ultimately severe encephalopathy with intractable epilepsy and hepatic failure. Childhood myocerebrohepatopathy spectrum (MCHS) presents between the first few months of life and about age three years with developmental delay or dementia, lactic acidosis, and a myopathy with failure to thrive. Other findings can include liver failure, renal tubular acidosis, pancreatitis, cyclic vomiting, and hearing loss. Myoclonic epilepsy myopathy sensory ataxia (MEMSA) now describes the spectrum of disorders with epilepsy, myopathy, and ataxia without ophthalmoplegia. MEMSA now includes the disorders previously described as spinocerebellar ataxia with epilepsy (SCAE). The ataxia neuropathy spectrum (ANS) includes the phenotypes previously referred to as mitochondrial recessive ataxia syndrome (MIRAS) and sensory ataxia neuropathy dysarthria and ophthalmoplegia (SANDO). About 90% of persons in the ANS have ataxia and neuropathy as core features. Approximately two thirds develop seizures and almost one half develop ophthalmoplegia; clinical myopathy is rare. Autosomal recessive progressive external ophthalmoplegia (arPEO) is characterized by progressive weakness of the extraocular eye muscles resulting in ptosis and ophthalmoparesis (or paresis of the extraocular muscles) without associated systemic involvement; however, caution is advised because many individuals with apparently isolated arPEO at the onset develop other manifestations of POLG-related disorders over years or decades. Of note, in the ANS spectrum the neuropathy commonly precedes the onset of PEO by years to decades. Autosomal dominant progressive external ophthalmoplegia (adPEO) typically includes a generalized myopathy and often variable degrees of sensorineural hearing loss, axonal neuropathy, ataxia, depression, parkinsonism, hypogonadism, and cataracts (in what has been called "chronic progressive external ophthalmoplegia plus," or "CPEO+").</Attribute>
                <XRef ID="NBK26471" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">POLG-Related Disorders</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="5783" />
                <XRef ID="5783" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301791</ID>
                <ID Source="BookShelf">NBK26471</ID>
              </Citation>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">29517884</ID>
                <ID Source="BookShelf">NBK487393</ID>
              </Citation>
              <XRef ID="726" DB="Orphanet" />
              <XRef ID="C0205710" DB="MedGen" />
              <XRef ID="MONDO:0008758" DB="MONDO" />
              <XRef Type="MIM" ID="203700" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="6257" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="15731" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Mitochondrial Neurogastrointestinal Encephalopathy Disease, POLG-Related</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">MNGIE, POLG-RELATED</ElementValue>
                <XRef Type="MIM" ID="613662" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Mitochondrial DNA depletion syndrome 4b</ElementValue>
                <XRef ID="MONDO:0013350" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Mitochondrial DNA depletion syndrome 4B, MNGIE type</ElementValue>
                <XRef ID="Mitochondrial+DNA+depletion+syndrome+4B%2C+MNGIE+type/8898" DB="Genetic Alliance" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">MTDPS4B</ElementValue>
                <XRef Type="MIM" ID="613662" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="keyword">POLG-Related Disorders</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">POLG-related disorders comprise a continuum of overlapping phenotypes that were clinically defined long before their molecular basis was known. Most affected individuals have some, but not all, of the features of a given phenotype; nonetheless, the following nomenclature can assist the clinician in diagnosis and management. Onset of the POLG-related disorders ranges from infancy to late adulthood. Alpers-Huttenlocher syndrome (AHS), one of the most severe phenotypes, is characterized by childhood-onset progressive and ultimately severe encephalopathy with intractable epilepsy and hepatic failure. Childhood myocerebrohepatopathy spectrum (MCHS) presents between the first few months of life and about age three years with developmental delay or dementia, lactic acidosis, and a myopathy with failure to thrive. Other findings can include liver failure, renal tubular acidosis, pancreatitis, cyclic vomiting, and hearing loss. Myoclonic epilepsy myopathy sensory ataxia (MEMSA) now describes the spectrum of disorders with epilepsy, myopathy, and ataxia without ophthalmoplegia. MEMSA now includes the disorders previously described as spinocerebellar ataxia with epilepsy (SCAE). The ataxia neuropathy spectrum (ANS) includes the phenotypes previously referred to as mitochondrial recessive ataxia syndrome (MIRAS) and sensory ataxia neuropathy dysarthria and ophthalmoplegia (SANDO). About 90% of persons in the ANS have ataxia and neuropathy as core features. Approximately two thirds develop seizures and almost one half develop ophthalmoplegia; clinical myopathy is rare. Autosomal recessive progressive external ophthalmoplegia (arPEO) is characterized by progressive weakness of the extraocular eye muscles resulting in ptosis and ophthalmoparesis (or paresis of the extraocular muscles) without associated systemic involvement; however, caution is advised because many individuals with apparently isolated arPEO at the onset develop other manifestations of POLG-related disorders over years or decades. Of note, in the ANS spectrum the neuropathy commonly precedes the onset of PEO by years to decades. Autosomal dominant progressive external ophthalmoplegia (adPEO) typically includes a generalized myopathy and often variable degrees of sensorineural hearing loss, axonal neuropathy, ataxia, depression, parkinsonism, hypogonadism, and cataracts (in what has been called "chronic progressive external ophthalmoplegia plus," or "CPEO+").</Attribute>
                <XRef ID="NBK26471" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">POLG-Related Mitochondrial DNA Depletion Syndrome, MNGIE Form</Attribute>
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301791</ID>
                <ID Source="BookShelf">NBK26471</ID>
              </Citation>
              <XRef ID="298" DB="Orphanet" />
              <XRef ID="C3150914" DB="MedGen" />
              <XRef ID="MONDO:0013350" DB="MONDO" />
              <XRef Type="MIM" ID="613662" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="1528782" SubmissionDate="2018-03-05" DateLastUpdated="2022-12-11" DateCreated="2018-07-13">
        <ClinVarSubmissionID localKey="NM_002693.2:c.1615_1623delTTTCAACAA|MedGen:C1834846" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000784509" DateUpdated="2022-12-11" DateCreated="2018-07-13" Type="SCV" Version="2" SubmitterName="Genomic Research Center, Shahid Beheshti University of Medical Sciences" OrgID="504864" OrganizationCategory="laboratory" OrgAbbreviation="GRC" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2018-03-05">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Uncertain significance</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>inherited</Origin>
              <GeographicOrigin>Iran</GeographicOrigin>
              <Species TaxonomyId="9606">human</Species>
              <Age Type="minimum" age_unit="years">0</Age>
              <Age Type="maximum" age_unit="years">9</Age>
              <AffectedStatus>yes</AffectedStatus>
              <Gender>female</Gender>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles" integerValue="1" />
            </ObservedData>
            <ObservedData>
              <Attribute Type="VariantChromosomes" integerValue="1" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_002693.2:c.1615_1623delTTTCAACAA</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C1834846" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>WES-Mar 05 2018</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="1528783" SubmissionDate="2018-03-05" DateLastUpdated="2022-12-11" DateCreated="2018-07-13">
        <ClinVarSubmissionID localKey="NM_002693.2:c.1615_1623delTTTCAACAA|MedGen:C3150914" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000784510" DateUpdated="2022-12-11" DateCreated="2018-07-13" Type="SCV" Version="2" SubmitterName="Genomic Research Center, Shahid Beheshti University of Medical Sciences" OrgID="504864" OrganizationCategory="laboratory" OrgAbbreviation="GRC" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2018-03-05">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Uncertain significance</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>inherited</Origin>
              <GeographicOrigin>Iran</GeographicOrigin>
              <Species TaxonomyId="9606">human</Species>
              <Age Type="minimum" age_unit="years">0</Age>
              <Age Type="maximum" age_unit="years">9</Age>
              <AffectedStatus>yes</AffectedStatus>
              <Gender>female</Gender>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles" integerValue="1" />
            </ObservedData>
            <ObservedData>
              <Attribute Type="VariantChromosomes" integerValue="1" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_002693.2:c.1615_1623delTTTCAACAA</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C3150914" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>WES-Mar 05 2018</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="1528784" SubmissionDate="2018-03-05" DateLastUpdated="2022-12-11" DateCreated="2018-07-13">
        <ClinVarSubmissionID localKey="NM_002693.2:c.1615_1623delTTTCAACAA|MedGen:C0205710" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000784511" DateUpdated="2022-12-11" DateCreated="2018-07-13" Type="SCV" Version="2" SubmitterName="Genomic Research Center, Shahid Beheshti University of Medical Sciences" OrgID="504864" OrganizationCategory="laboratory" OrgAbbreviation="GRC" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2018-03-05">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Uncertain significance</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>inherited</Origin>
              <GeographicOrigin>Iran</GeographicOrigin>
              <Species TaxonomyId="9606">human</Species>
              <Age Type="minimum" age_unit="years">0</Age>
              <Age Type="maximum" age_unit="years">9</Age>
              <AffectedStatus>yes</AffectedStatus>
              <Gender>female</Gender>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles" integerValue="1" />
            </ObservedData>
            <ObservedData>
              <Attribute Type="VariantChromosomes" integerValue="1" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_002693.2:c.1615_1623delTTTCAACAA</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0205710" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>WES-Mar 05 2018</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="3923885" SubmissionDate="2023-07-12" DateLastUpdated="2023-07-16" DateCreated="2021-11-06">
        <ClinVarSubmissionID localKey="Chr.15_89326700_89326709_CTTGTTGAAA_C|not provided" />
        <ClinVarAccession Accession="SCV002010404" DateUpdated="2023-07-16" DateCreated="2021-11-06" Type="SCV" Version="3" SubmitterName="Institute for Clinical Genetics, University Hospital TU Dresden, University Hospital TU Dresden" OrgID="505632" OrganizationCategory="clinic" OrgAbbreviation="KGE" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2021-11-03">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>not provided</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <Location>
            <SequenceLocation Assembly="GRCh38" Chr="15" alternateAllele="C" referenceAllele="CTTGTTGAAA" start="89326700" stop="89326709" />
          </Location>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">not provided</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB10612882</SubmissionName>
          <SubmissionName>SUB13603663</SubmissionName>
          <SubmissionName>SUB13676335</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="6204869" SubmissionDate="2024-02-08" DateLastUpdated="2024-02-14" DateCreated="2023-02-07">
        <ClinVarSubmissionID localKey="4413081|MedGen:C0205710" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV003514419" DateUpdated="2024-02-14" DateCreated="2023-02-07" Type="SCV" Version="2" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2024-01-25">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Uncertain significance</GermlineClassification>
          <Comment>This variant, c.1615_1623del, results in the deletion of 3 amino acid(s) of the POLG protein (p.Phe539_Gln541del), but otherwise preserves the integrity of the reading frame. This variant is present in population databases (rs754586219, gnomAD 0.002%). This variant has not been reported in the literature in individuals affected with POLG-related conditions. ClinVar contains an entry for this variant (Variation ID: 548594). Experimental studies and prediction algorithms are not available or were not evaluated, and the functional significance of this variant is currently unknown. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="POLG" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000015.9:g.89869932_89869940del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0205710" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB12508014</SubmissionName>
          <SubmissionName>SUB14200283</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="1528782" TraitType="Disease" MappingType="XRef" MappingValue="C1834846" MappingRef="MedGen">
        <MedGen CUI="C1834846" Name="Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant 1" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1528784" TraitType="Disease" MappingType="XRef" MappingValue="C0205710" MappingRef="MedGen">
        <MedGen CUI="C0205710" Name="Progressive sclerosing poliodystrophy" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="3923885" TraitType="Disease" MappingType="Name" MappingValue="not provided" MappingRef="Preferred">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1528783" TraitType="Disease" MappingType="XRef" MappingValue="C3150914" MappingRef="MedGen">
        <MedGen CUI="C3150914" Name="Mitochondrial DNA depletion syndrome 4b" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="6204869" TraitType="Disease" MappingType="XRef" MappingValue="C0205710" MappingRef="MedGen">
        <MedGen CUI="C0205710" Name="Progressive sclerosing poliodystrophy" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

